Navigation Links
Study Offers Clues to Why Some Don't Benefit From Asthma Drugs
Date:1/6/2012

By Kathleen Doheny
HealthDay Reporter

FRIDAY, Jan. 6 (HealthDay News) -- Almost half of patients with mild or moderate asthma may have a different type of disease than those with more severe symptoms, perhaps explaining why common treatments don't work well for them, new research suggests.

"We are beginning to understand that different 'flavors' of asthma probably have different molecular mechanisms," said Dr. John Fahy, director of the Airway Clinical Research Center at the University of California, San Francisco. He is the senior author of the new study, published online Friday in the American Journal of Respiratory and Critical Care Medicine.

Asthma is a chronic disease involving inflamed airways. As the airways become more swollen, the muscles around them can tighten when something triggers symptoms such as coughing, wheezing and shortness of breath.

Current anti-inflammatory treatments target a condition called eosinophilic airway inflammation, which is common in asthma. Eosinophils are a type of white blood cell that help fight off infection and play a role in the immune response.

However, the new research finds that nearly half of the 995 patients studied did not have this condition.

Fahy's team repeatedly measured these white blood cells in sputum samples of the volunteers with asthma who were enrolled in nine clinical trials.

Nearly half, or 47 percent, had no airway eosinophilia on any test of their sputum. Some had the condition intermittently and some had it on each test.

The investigators found that only 36 percent of those not taking an inhaled corticosteroid, an anti-inflammatory, had the condition, while 17 percent of those who used the inhaled steroids did.

After two weeks of giving the participants anti-inflammatories and bronchodilator therapy, Fahy found those with the airway eosinophilia responded and had better airflow. But those who didn't have the condition did not respond. The responses to the bronchodilators -- other medicines commonly used for asthma that work by helping to open the bronchial tubes -- were similar in both groups, however.

Previous studies looked at a single sample to assess whether those with asthma had the white blood cell involvement, Fahy explained, while this study looked at many over time.

"This study reinforces the idea that asthma is not a one-type disease," he said.

Even within the nearly 50 percent without the white blood cell involvement, there are probably many different subtypes, Fahy noted.

The test used was a complicated research test, Fahy pointed out, and it is not easily done in clinical practice.

Based on the study results, researchers might next work on a simpler test to determine if those with asthma have involvement of these white blood cells, he said. Eventually, the findings may help doctors better individualize asthma treatment.

The findings suggest that a sizeable group of people with mild to moderate asthma have a type of disease that is not typical, with poorly understood mechanisms, and that new treatments will be needed, Fahy concluded.

"The finding that half of these had the absence of eosinophils in the sputum was a little surprising," said Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City.

"It's higher than I thought," Horovitz said. The "cascade" of inflammation in asthma -- what happens to bring on the symptoms -- has been well studied, he noted. However, "we can't guarantee that our current regimen of bronchodilators plus inhaled corticosteroids is going to work, even in mild asthma," Horovitz explained.

Doctors should ask their patients with asthma if they produce a lot of sputum, Horovitz suggested. If they do, they tend to respond to the corticosteroids.

More information

To learn more about asthma, visit the American Academy of Allergy, Asthma and Immunology.

SOURCES: John V. Fahy, M.D., director, Airway Clinical Research Center, University of California, San Francisco; Len Horovitz, M.D., internist and pulmonary specialist, Lenox Hill Hospital, New York City; Jan. 6, 2012, American Journal of Respiratory and Critical Care Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Mice Exposed to Smoke Helped by Blood Pressure Drug: Study
2. Global Study Finds Drug Abuse Highest in Richer Nations
3. Diabetes Care Thwarted by Unstable Health Insurance: Study
4. Moderate red wine drinking may help cut womens breast cancer risk, Cedars-Sinai study shows
5. Mental Decline Can Start at 45, Study Finds
6. Study finds statin costs 400 percent higher in US compared to UK
7. Drug Eases Gout Flare-ups in Some Patients: Study
8. Study Reveals Whos More Prone to Be a Mean Drunk
9. Kaiser Permanente study finds continuous health coverage essential for patients managing diabetes
10. Safety-First Playgrounds Linked to Bored, Inactive Kids: Study
11. U-M study shows updated rotavirus vaccine not linked to increase in bowel obstruction
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Offers Clues to Why Some Don't Benefit From Asthma Drugs
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: